Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.

[1]  Andrew G. Leach,et al.  Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes. , 2012, Bioorganic & medicinal chemistry letters.

[2]  M. Pruniaux,et al.  Thiadiazoles as new inhibitors of diacylglycerol acyltransferase type 1. , 2012, Bioorganic & medicinal chemistry letters.

[3]  Steven C. Cullen,et al.  Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1. , 2012, Journal of medicinal chemistry.

[4]  D. A. Pan,et al.  Design and synthesis of potent carboxylic acid DGAT1 inhibitors with high cell permeability. , 2012, Bioorganic & medicinal chemistry letters.

[5]  Yingsi Chen,et al.  Discovery and optimization of 2-phenyloxazole derivatives as diacylglycerol acyltransferase-1 inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[6]  R. Vishwakarma,et al.  Exploration of pyridine containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[7]  Eliot Sugarman,et al.  Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1. , 2011, ACS medicinal chemistry letters.

[8]  C. Rondinone,et al.  Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes. , 2011, Journal of medicinal chemistry.

[9]  Masahiro Tanaka,et al.  Discovery of pyrrolopyridazines as novel DGAT1 inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[10]  T. Turner,et al.  Novel acyl coenzyme A (CoA): diacylglycerol acyltransferase-1 inhibitors: synthesis and biological activities of diacylethylenediamine derivatives. , 2010, Bioorganic & medicinal chemistry.

[11]  S. Summers,et al.  Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms. , 2010, Biochimica et biophysica acta.

[12]  A. Souers,et al.  Inhibitors of diacylglycerol acyltransferase: a review of 2008 patents , 2010, Expert opinion on therapeutic patents.

[13]  Robert V Farese,et al.  Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. , 2008, Journal of lipid research.

[14]  A. Souers,et al.  Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. , 2008, Journal of medicinal chemistry.

[15]  Robert V Farese,et al.  Lipopenia and Skin Barrier Abnormalities in DGAT2-deficient Mice* , 2004, Journal of Biological Chemistry.

[16]  Robert V Farese,et al.  Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. , 2002, The Journal of clinical investigation.

[17]  G. Lewis,et al.  Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. , 2002, Endocrine reviews.

[18]  Robert V Farese,et al.  Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat , 2000, Nature Genetics.